Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00959049 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population
A Phase 3 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,474
- Enrollment target
NCT00959049: Completed Phase 3 study, sponsored by Seqirus.
NCT00959049 is a Phase 3 study that has completed, run by Seqirus. The registered enrollment target is 1,474 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00959049, a Phase 3 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,474 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US licensed comparator Influenza Virus Vaccine in a pediatric population aged greater than or equal to 6 months to less than 18 years.
Interventions
- BIOLOGICAL CSL's Influenza Virus Vaccine (Afluria)
- BIOLOGICAL Influenza Virus Vaccine (Fluzone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,474 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
What the finished NCT00959049 record still lists
NCT00959049 is an interventional study that assigns participants to a tested intervention. Its 1,474 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% higher).
The record links to 0 conditions, and to 2 interventions - of which CSL's Influenza Virus Vaccine (Afluria) is the first listed.
NCT00959049 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00959049 about?
NCT00959049 is a clinical study titled "A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population". The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US licensed comparator Influenza Virus Vaccine in a pediatric population aged greater than or equal to 6 months to less than 18 years.
What is the current status of trial NCT00959049?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,474 participants. The study started on 2009-09. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00959049?
The interventions under investigation include: CSL's Influenza Virus Vaccine (Afluria) (BIOLOGICAL), Influenza Virus Vaccine (Fluzone) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00959049?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00959049's enrollment target sits among peer trials
1,474 163rd of 2000 higher than 1,838 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05869552 · 1,485 participants · NA
Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia